Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
99.26%
0%
99.26%
6 Months
95.63%
0%
95.63%
1 Year
363.31%
0%
363.31%
2 Years
109.36%
0%
109.36%
3 Years
22.9%
0%
22.9%
4 Years
-35.39%
0%
-35.39%
5 Years
-26.21%
0%
-26.21%
DBV Technologies SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-23.41%
EBIT to Interest (avg)
-88.72
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.48
Sales to Capital Employed (avg)
0.00
Tax Ratio
6.71%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.09
EV to EBIT
-2.55
EV to EBITDA
-2.82
EV to Capital Employed
-37.80
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-119.71%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-33.50
-28.70
-16.72%
Interest
0.60
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-36.90
-30.80
-19.81%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -19.81% vs -38.12% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-105.30
-89.40
-17.79%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-105.30
-67.30
-56.46%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -56.46% vs 26.53% in Dec 2023
About DBV Technologies SA 
DBV Technologies SA
Pharmaceuticals & Biotechnology
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
Company Coordinates 
Company Details
177-181 avenue Pierre Brossolette , MONTROUGE None : 92120
Registrar Details






